mProX™ Human CHRM3 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX639	Magic™ Rat CHRM3 in Vitro Calcium Flux Assay	Rat	CHO-K1	Calcium Flux Assay

Product Information

Target Protein

CHRM3

Target Family

Muscarinic Acetylcholine Family

Target Protein Species

Human

Host Cell Type

PC3;CHO-K1;HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Metabolic Research

Related Diseases

Prune Belly Syndrome;Overactive Bladder Syndrome

Gene ID

Human: 1131

UniProt ID

Human: P20309

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CHRM3 is another member of the muscarinic acetylcholine receptor family, with its implications in various physiological and pathological processes. Recent studies have highlighted the role of CHRM3 in glioma, where its aberrant expression may contribute to tumor progression. Additionally, CHRM3 has been linked to cholinergic urticaria, where its reduced expression in sweat glands may contribute to impaired sweating responses. The receptor's involvement in sleep disturbances, particularly in the context of Alzheimer's disease, further underscores its significance in neurological research.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CHRM3 Stable Cell Line (S01YF-0923-PY129). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Barbara (Verified Customer)

What role does CHRM3 play in glioma? Nov 20 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

CHRM3-AS2, a long non-coding RNA associated with CHRM3, has been identified as a prognosis-associated differentially expressed RNA in glioblastoma (GBM). It is involved in mechanisms related to miR-370-5p/KLF4 in glioma. Nov 20 2022

chat Dorothy (Verified Customer)

How is CHRM3 linked to cholinergic urticaria and sweating? Aug 02 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

Patients with cholinergic urticaria who have impaired sweating responses show reduced sweat gland epithelial expression of CHRM3. This reduction is associated with prolonged disease duration and increased disease severity. Aug 02 2022

Published Data

Fig.1 CHRM3 knockdown inhibited tumor development in vivo.

In an effort to expand the scope of their in vitro investigations to an in vivo context, researchers subcutaneously introduced PC3 cells with CHRM3 knockdown into BALB/c nude mice. This experimental approach yielded noteworthy results, as it was observed that the suppression of CHRM3 effectively hindered tumor progression within the in vivo setting. These findings were substantiated by statistical analysis employing the Student t-test (n = 9 mice), demonstrating a significant reduction in the growth of PC3 cells due to CHRM3 shRNA treatment (***, P < 0.001).

Ref: Wang, Naitao, et al. "Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMKK-mediated phosphorylation of Akt." Clinical cancer research 21.20 (2015): 4676-4685.

Pubmed: 26071486

DOI: 10.1158/1078-0432.CCR-14-3163

Research Highlights

Zhang B, et al. "CHRM3 is a novel prognostic factor of poor prognosis and promotes glioblastoma ." Oncology research, 2023.
Glioblastoma (GBM) is known to be the most aggressive form of brain cancer with a high mortality rate attributed to the lack of effective treatment strategies. There is an urgent need to clarify the molecular mechanisms that drive GBM's invasive growth in order to improve patient prognosis. Through single-nuclear sequencing of primary and recurrent GBM samples, it was discovered that the levels of M3 muscarinic acetylcholine receptor (CHRM3) were significantly elevated in the recurrent samples compared to the primary ones. Further immunohistochemical staining of a range of GBM samples confirmed a correlation between high levels of CHRM3 and poor prognosis, consistent with The Cancer Genome Atlas database. Inhibition of CHRM3 was found to suppress GBM cell growth and invasion in vitro and in an orthotopic GBM animal model in vivo, leading to a significant increase in overall survival time. Moreover, transcriptome analysis revealed that CHRM3 knockdown reduced the expression of a number of classic factors implicated in cancer invasive growth, such as MMP1/MMP3/MMP10/MMP12 and CXCL1/CXCL5/CXCL8. These findings suggest that CHRM3 plays a crucial role in the progression of GBM by regulating multiple oncogenic genes and may serve as a potential biomarker for the prognosis and treatment of GBM patients.
Pubmed: 37744266 DOI: 10.32604/or.2023.030425

Seibert FS, et al. "Severity of neurological Long-COVID symptoms correlates with increased level of ." Autoimmunity reviews, 2023.
The Long-COVID syndrome encompasses various ongoing symptoms, with the most disabling being neurological disorders. The cause of this condition is currently under scrutiny, with conflicting data on the role of autoimmune reactions to G-protein coupled receptors (GPCR). A cross-sectional study was conducted on individuals who had a mild to moderate SARS-CoV-2 infection within the last 12 months. The study measured levels of autoantibodies specific to vasoregulation-associated receptors and quantified neurological disorders using standardized questionnaires. The results showed significantly higher levels of autoantibodies in Long-COVID patients compared to those without a diagnosis or history of SARS-CoV-2 infection. These autoantibodies were also found to be associated with various neurological symptoms such as psychomotor speed, visual searching, attention, and fatigue.
Pubmed: 37689093 DOI: 10.1016/j.autrev.2023.103445